郑焱玲,陈刘,刘颖,唐能华,欧敏,雷小添,程立庆,龙崇荣
ZHENG Yanling,CHEN Liu,LIU Ying,TANG Nenghua,OU Min,LEI Xiaotian,CHENG Liqing,LONG Chongrong

• 1:第三军医大学西南医院内分泌科
• 2:重庆市沙坪坝区人民医院内分泌科

摘要(Abstract)：

目的:观察曲美他嗪辅助治疗糖尿病心肌病(DC)的临床疗效。方法:将156例DC患者按随机数字法分为治疗组(81例)与对照组(75例),采用常规内科治疗;治疗组在常规内科治疗基础上口服曲美他嗪,测定治疗前后各组的空腹血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白、E/A比值、心电图Q-T离散度(Q-Td),超敏C反应蛋白(HsCRP)和肿瘤坏死因子(TNF-α)。结果:与治疗前比较,两组患者治疗后血糖、总胆固醇、甘油三酯、LDL、HDL均较治疗前有所改善(P<0.05),其中治疗组总胆固醇、甘油三酯、LDL、HDL改善幅度较对照组大(P<0.05);Q-Td均较治疗前有所降低(P<0.05),其中治疗组降低幅度较对照组幅度大(P<0.05);E/A比值均较治疗前有显著增高(P<0.05),其中治疗组改善幅度较对照组显著(P<0.05);HsCRP和TNF-α均较治疗前下降明显(P<0.05),其中治疗组HsCRP和TNF-α改善幅度与对照组相比更为明显(P<0.05)。结论:曲美他嗪对临床糖尿病心肌病有一定辅助治疗效果。
Objective: To investigate the efficacy of Trimetazidine in 156 patients with diabetic cardiomyopathy. Methods: 156 patients were randomly divided into Trimetazidine treatment group( n =81) and the control group( n = 75),both received conventional medical treatment. Treatment group received further Trimetazidine treatment. Blood glucose,HbA1C,blood lipids( total cholesterol,triglycerides,LDL,HDL),E/A ratio,ECG QT dispersion,High-sensitive C-reactive protein( HsCRP)and TNF-αwere tested before and after treatment. Results: Compared with before treatment,blood glucose,total cholesterol,triglycerides,LDL,HDL were improved significantly in both group after treatment( P < 0. 05); in treatment group,total cholesterol,triglycerides,LDL,HDL improved much more than control group( P < 0. 05); QT dispersion decreased compared with before treatment( P < 0.05),of which treatment decreased much more tan control group( P < 0. 05); E/A ratio improved compared with before treatment( P < 0. 05),of which treatment group improved much more than control group( P < 0. 05); HsCRP and TNF-αdecreased compared with before treatment( P < 0. 05),of which HsCRP and TNF-α improvement were more obvious compared with control group( P < 0. 05). Conclusion: Trimetazidine can assist the treatment of diabetic cardiomyopathy.

关键词(KeyWords)： 曲美他嗪;糖尿病;心肌病;治疗效果;心功能;超敏C反应蛋白;肿瘤坏死因子
trimetazidine;diabetes;cardiomyopathy;curative effects;heart function;hypersensitive C reactive protein;tumor necrosis factor

Abstract:

Keywords:

基金项目(Foundation): 中华医学会临床医学科研专项资金(13040630448);; 中华国际医学交流基金会青年医生糖尿病研究项目(2015-N-08)

作者(Author): 郑焱玲,陈刘,刘颖,唐能华,欧敏,雷小添,程立庆,龙崇荣
ZHENG Yanling,CHEN Liu,LIU Ying,TANG Nenghua,OU Min,LEI Xiaotian,CHENG Liqing,LONG Chongrong

DOI: 10.19367/j.cnki.1000-2707.2017.12.023

参考文献(References)：

• [1]Liu J,Liu Y,Chen L,et al.Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway[J].J Diabetes Res,2013(2013):630537-630539.
• [2]Mizamtsidi M,Paschou SA,Grapsa J,et al.Diabetic cardiomyopathy:a clinical entity or a cluster of molecular heart changes[J].Eur J Clin Invest,2016(11):947-953.
• [3]Sanda D,Kenneth B,Margulies,et al.Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes a study in humans and rats[J].Circ Res,2012(4):598-608.
• [4]Gil KE,Pawlak A,Gil RJ,et al.The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy:A systematic review[J].Adv Med Sci,2016(2):331-343.
• [5]Dei Cas A,Khan SS,Butler J,et al.Impact of diabetes on epidemiology,treatment,and outcomes of patients with heart failure[J].JACC Heart Fail,2015(2):136-145.
• [6]Imène TA,Cécile HT,Didier M,et al.Prevention of heart failure in rats by trimetazidine ttreatment:a consequence of Accelerated phospholipid turnover[J].Journal of Pharmacology And Experimental Therapeutics Fast Forward,2003(3):1003-1009.
• [7]Zou H,Zhu XX,Ding YH,et al.Trimetazidine in conditions other than coronary disease,old drug,new tricks[J].Int J Cardiol,2017(1):1-6.
• [8]Zhou X,Chen J.Is treatment with trimetazidine beneficial in patients with chronic heart failure[J].PLo S One,2014(5):e94660-e94666.
• [9]Fang ZY,Prins JB,Marwick TH.Diabetic cardiomyopathy:evidence,mechanisms,and therapeutic implications[J].Endocr,2004(6):543-567.
• [10]Liu Z,Chen JM,Huang H,et al.The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway[J].Metabolism,2016(3):122-130.
• [11]Martins GF,Siqueira Filho AG,Santos JB,et al.Trimetazidine on ischemic injury and reperfusion in coronary artery bypass grafting[J].Arq Bras Cardiol,2011(3):209-216.
• [12]Yao X,Li Y,Tao M,et al.Effects of glucose concentration on propofol cardioprotection against myocardial ischemia reperfusion injury in isolated rat hearts[J].J Diabetes Res,2015(2015):592028-592036.
• [13]Yamanaka F,Jeong MH,Saito S,et al.Comparison of clinical outcomes between octogenarians and non-octogenarians with acute myocardial infarction in the drug-eluting stent era:analysis of the korean acute myocardial infarction registry[J].J Cardiol,2013(4):210-216.
• [14]Momen A,Ali M,Karmakar PK,et al.Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy-Six months follow-up result[J].Indian Heart J,2016(6):809-815.
• [15]Ussher JR,Fillmore N,Keung W,et al.Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice[J].Can J Cardiol,2014(8):940-944.
• [16]Li YJ,Wang PH,Chen C,et al.Improvement of mechanical heart function by trimetazidine in db/db mice[J].Acta Pharmacol Sin,2010(5):560-569.
• [17]Lijnen PJ,van Pelt JF,Fagard RH.Stimulation of reactive oxygen species and collagen synthesis by angiotensin II in cardiac fibroblasts[J].Cardiovasc Ther,2012(1):e1-8.
• [18]Gao D,Ning N,Niu X,et al.Trimetazidine:a meta-analysis of randomised controlled trials in heart failure[J].Heart,2011(3):278–286.
• [19]Chen A,Li W,Chen X,et al.Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction[J].BMC Cardiovasc Disord,2016(1):225-227.
• [20]Dézsi CA.Trimetazidine in practice:review of the clinical and experimental evidence[J].Am J Ther,2016(3):e871-e879.
• [21]Mc Carthy CP,Mullins KV,Kerins DM.The role of trimetazidine in cardiovascular disease:beyond an anti-anginal agent[J].Eur Heart J Cardiovasc Pharmacother,2016(4):266-272.
• [22]Fragasso G,Salerno A,Spoladore R,et al.Effects of metabolic approach in diabetic patients with coronary artery disease[J].Curr Pharm Des,2009(8):857-862.
• [23]Ambrosio G,Tamargo J,Grant PJ.Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes:A review of the evidence[J].Diab Vasc Dis Res,2016(2):98-112.
• [24]Tuunanen H,Engblom E,Naum A,et al.Trimetazidine,a metabolic modulator,has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy[J].Circulation,2008(12):1250-1258.
• [25]Jianxue BO,Yuan B.Effects of combined treatment with trimetazidine and atorvastatin on myocardial protection of patients under-going percutaneous coronary intervention[J].Pharmaceutical Care&Research,2011(2):107-110.

文章评论(Comment)：